Jan 21 Covidien Plc said it would stop
making devices for treating high blood pressure due to weak
The device, known as a renal denervation system, belongs to
a class of products that take a new approach to treating
hypertension and are aimed at patients resistant to traditional
Covidien's device is approved in Europe and is being tested
in the United States. The adoption of such devices has been slow
as austere governments are reluctant to pay for the
These devices work by creating tiny scars along nerves in
the kidneys - organs that play a pivotal role in regulating
blood pressure by sending signals to the brain that can cause
blood vessels to constrict.
This scarring process is carried out by threading a catheter
through the renal arteries from the groin. It deadens the nerves
and decreases blood pressure.
Covidien said the decision to exit the business was a result
of its regular review of strategic programs.
Covidien said it expects to record after-tax charges of
$20-$25 million as a result of exiting the program.
The company's shares were unchanged in light premarket
trading on Tuesday.